°û½Â±â ¸íÀÇ

Á¤Á÷ÇÏ°í ¼º½ÇÇÑ Áø·á, ÀÚ°¡¸é¿ªÁúȯ ¸íÀÇ

°û½Â±â ¸íÀÇ

  • ¼Ò ¼Ó
    °¡Å縯´ë¼­¿ï¼º¸ðº´¿ø ·ù¸¶Æ¼½º³»°ú
  • Àü¹®ºÐ¾ß
    ·çǪ½º,¼î±×·»ÁõÈıº,Àü½Å°æÈ­Áõ,·ù¸¶Æ¼½º°üÀý¿°,°­Á÷¼ºÃ´Ãß¿°,º£Ãº´
°û½Â±â ±³¼ö´Â ¿ì¸®³ª¶ó¿¡¼­ óÀ½À¸·Î ³»°ú ¿Ü·¡¿¡¼­ ·ù¸¶Æ¼½º ȯÀÚÀÇ Áø·á¸¦ ½ÃÀÛÇÑ ¼­¿ï¼º¸ðº´¿ø¿¡¼­ ÀÚ°¡¸é¿ªÁúȯÀÇ ¸íÀǷΠȯÀÚ¸¦ Ä¡·áÇϰí ÀÖ´Ù. Áø·á »Ó ¾Æ´Ñ ¿¬±¸Àڷμ­ »õ·Î¿î Ä¡·á¹ýÀ» °³¹ßÇϱâ À§ÇØ ³ë·ÂÇϰí Àִµ¥, 2009³âºÎÅÍ ¸é¿ªÇÐ ºÐ¾ßÀÇ È°¹ßÇÑ ±âÃÊ ¹× ÀÌÇ༺ ¿¬±¸¸¦ ¼öÇàÇØ ¸é¿ªÇÐ ¹ßÀü¿¡ À̹ÙÁöÇÏ¿´°í 2023³â¿¡´Â ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ Ãѹ«À§¿øÀåÀ» ¿ªÀÓÇÏ¸ç ¸é¿ªÇÐÀÇ Çй®Àû ¹ßÀü°ú Àü¹®°¡ ´Üü·Î¼­ÀÇ »çȸÀû Ã¥¹«¿¡ Èû½á ÇÐȸÀÇ µµ¾àÀ» À̲ø¾î °úÇбâ¼úÁ¤º¸Åë½ÅºÎÀå°ü ǥâÀ» ¼ö»óÇß´Ù.

¸íÀÇÇÁ·ÎÇÊ ¸íÀÇ ÇÁ·ÎÇÊ

ÇзÂ

  • °¡Å縯´ë ÀÇ´ë Çлç
  • °¡Å縯´ë ÀÇ´ë ¼®»ç
  • °¡Å縯´ë ÀÇ´ë ¹Ú»ç

ÁÖ¿ä°æ·Â

  • úÞ) ¼­¿ï¼º¸ðº´¿ø ·ù¸¶Æ¼½º³»°ú ±³¼ö
  • ¼­¿ï¼º¸ðº´¿ø ·ù¸¶Æ¼½º³»°ú ºÎ±³¼ö (2013 ~ 2016)
  • ¼­¿ï¼º¸ðº´¿ø ·ù¸¶Æ¼½º³»°ú Á¶±³¼ö (2009 ~ 2013)

¼ö»ó³»¿ª

  • °úÇбâ¼úÁ¤º¸Åë½ÅºÎÀå°ü ǥâ ¼ö»ó (2023)
  • ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ ¿ì¼ö³í¹®»ó (2017)
  • ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ ÀþÀº ¿¬±¸ÀÚ»ó (2016)
  • ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ ¿ì¼ö±¸¿¬»ó (2015)

ÁýÇÊÀú¼­

ÃÑ 0°Ç

ÁÖ¿ä³í¹®

ÃÑ 4°Ç
Á¦ ¸ñ A single-centre retrospective study of factors affecting steroid-free remission of immunoglobulin G4-related disease conducted in South Korea: A notable outcome after complete resection
¹ßÇ¥³âµµ 2024.05
¹ßÇ¥Áö MODERN RHEUMATOLOGY
Á¦ ¸ñ Kynurenine pathway can be a potential biomarker of fatigue in primary Sjögren's syndrome
¹ßÇ¥³âµµ 2023.12
¹ßÇ¥Áö CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
Á¦ ¸ñ Predictors for future development of systemic lupus erythematosus in Korean Sjogren's syndrome patients
¹ßÇ¥³âµµ 2023.10
¹ßÇ¥Áö LUPUS
Á¦ ¸ñ Mesenchymal Stem/Stromal Cell-Based Therapies in Systemic Rheumatic Disease: From Challenges to New Approaches for Overcoming Restrictions
¹ßÇ¥³âµµ 2023.06
¹ßÇ¥Áö INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

¸íÀÇqna ¸íÀÇ QnA

°¡Àå °ü½É ÀÖ´Â ºÐ¾ß¿Í ¾÷ÀûÀÌ ÀÖ´Ù¸é ¾Ë·ÁÁÖ¼¼¿ä
ȯÀÚ Áø·á¿¡ ÀÖ¾î °¡Àå Áß¿äÇÏ°Ô »ý°¢ÇÏ´Â °¡Ä¡´Â?
ȯÀڵ鿡°Ô ÀüÇÏ°í ½ÍÀº ¸»¾¸

¸íÀÇqna ¸íÀÇ ¼Ò¼Óº´¿ø

°¡Å縯´ë¼­¿ï¼º¸ðº´¿ø

»ó±ÞÁ¾ÇÕº´¿ø
ÀüÈ­ ¾ÆÀÌÄÜ ´ëÇ¥¹øÈ£
1588-1511
À¥»çÀÌÆ® ¾ÆÀÌÄÜȨÆäÀÌÁö
°¡Å縯´ë¼­¿ï¼º¸ðº´¿ø À̹ÌÁö

ÁÖ¿ä½Ã¼³

ÀÀ±Þ½Ç ÀÀ±Þ½Ç
Ŭ¸®´Ð Ŭ¸®´Ð
Á¾ÇÕ°ËÁø¼¾ÅÍ Á¾ÇÕ°ËÁø¼¾ÅÍ
¾Ï¼¾ÅÍ ¾Ï¼¾ÅÍ
ÁÖÂ÷½Ã¼³ ÁÖÂ÷½Ã¼³

°¡Å縯´ë¼­¿ï¼º¸ðº´¿øÀº 1980³â °­³² Áö¿ª ÃÖÃÊÀÇ Á¾ÇÕº´¿øÀ¸·Î ¼¼¿öÁ³´Ù. ÇöÀç Áö»ó 22Ãþ, ÁöÇÏ 6ÃþÀÇ 1355º´»ó ±Ô¸ð¸¦ °®Ãß°í ÀÖÀ¸¸ç ´ÜÀÏ °Ç¹° º´¿øÀ¸·Î´Â ±¹³» ÃÖ´ë ±Ô¸ðÀÌ´Ù. °¡Å縯´ë¼­¿ï¼º¸ðº´¿øÀº °¡Å縯±³È¸ÀÇ ´ëÇ¥ º´¿øÀ¸·Î °¡Å縯Áß¾ÓÀÇ·á¿øÀÇ ÀÌ³ä ½Çõ¿¡ Àû±Ø ¾ÕÀå¼­°í ÀÖÀ¸¸ç, ȯÀÚ¸¦ ¸ÕÀú »ý°¢ÇÏ´Â Àü¹®¼¾ÅÍ Áß½ÉÀÇ º´¿ø, 21¼¼±â ÃÖ÷´Ü ÀÇ·á ½Ã½ºÅÛ º´¿øÀ¸·Î °Åµì³ª°í ÀÖ´Ù.

¼­¿ïƯº°½Ã ¼­Ãʱ¸ ¹ÝÆ÷´ë·Î 222

Ȩ
³»°¡ ¾Ë°íÀÖ´Â ¸íÀǸ¦ ÃßÃµÇØÁÖ¼¼¿ä